vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Velocity Financial, Inc. (VEL). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $51.6M, roughly 1.5× Velocity Financial, Inc.). Velocity Financial, Inc. runs the higher net margin — 67.3% vs -9.6%, a 76.9% gap on every dollar of revenue. On growth, Velocity Financial, Inc. posted the faster year-over-year revenue change (32.8% vs -16.8%). Over the past eight quarters, Velocity Financial, Inc.'s revenue compounded faster (32.3% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Velocity Financial, Inc. is a U.S.-headquartered real estate finance company that offers specialized mortgage loan solutions primarily for residential investment properties. It partners with independent mortgage brokers nationwide, providing real estate investors with short-term bridge loans and long-term rental property financing options tailored to their operational needs.

BIOX vs VEL — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.5× larger
BIOX
$77.6M
$51.6M
VEL
Growing faster (revenue YoY)
VEL
VEL
+49.6% gap
VEL
32.8%
-16.8%
BIOX
Higher net margin
VEL
VEL
76.9% more per $
VEL
67.3%
-9.6%
BIOX
Faster 2-yr revenue CAGR
VEL
VEL
Annualised
VEL
32.3%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
VEL
VEL
Revenue
$77.6M
$51.6M
Net Profit
$-7.4M
$34.8M
Gross Margin
46.8%
Operating Margin
9.3%
97.0%
Net Margin
-9.6%
67.3%
Revenue YoY
-16.8%
32.8%
Net Profit YoY
-20.2%
67.0%
EPS (diluted)
$-0.12
$0.90

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
VEL
VEL
Q4 25
$51.6M
Q3 25
$77.6M
$49.1M
Q2 25
$47.6M
Q1 25
$60.6M
$37.5M
Q4 24
$98.8M
$38.9M
Q3 24
$93.3M
$35.1M
Q2 24
$32.4M
Q1 24
$84.0M
$29.5M
Net Profit
BIOX
BIOX
VEL
VEL
Q4 25
$34.8M
Q3 25
$-7.4M
$25.4M
Q2 25
$26.0M
Q1 25
$-1.6M
$18.9M
Q4 24
$605.2K
$20.8M
Q3 24
$-6.2M
$15.8M
Q2 24
$14.8M
Q1 24
$9.8M
$17.3M
Gross Margin
BIOX
BIOX
VEL
VEL
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
VEL
VEL
Q4 25
97.0%
Q3 25
9.3%
72.1%
Q2 25
71.3%
Q1 25
1.5%
71.7%
Q4 24
14.5%
82.5%
Q3 24
2.5%
60.6%
Q2 24
61.3%
Q1 24
15.7%
78.8%
Net Margin
BIOX
BIOX
VEL
VEL
Q4 25
67.3%
Q3 25
-9.6%
51.7%
Q2 25
54.6%
Q1 25
-2.6%
50.4%
Q4 24
0.6%
53.5%
Q3 24
-6.6%
45.1%
Q2 24
45.6%
Q1 24
11.6%
58.5%
EPS (diluted)
BIOX
BIOX
VEL
VEL
Q4 25
$0.90
Q3 25
$-0.12
$0.65
Q2 25
$0.69
Q1 25
$-0.02
$0.51
Q4 24
$0.00
$0.56
Q3 24
$-0.10
$0.44
Q2 24
$0.42
Q1 24
$0.14
$0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
VEL
VEL
Cash + ST InvestmentsLiquidity on hand
$15.5M
$92.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$672.5M
Total Assets
$734.9M
$7.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
VEL
VEL
Q4 25
$92.1M
Q3 25
$15.5M
$99.0M
Q2 25
$79.6M
Q1 25
$38.5M
$51.7M
Q4 24
$29.2M
$49.9M
Q3 24
$32.3M
$44.1M
Q2 24
$47.4M
Q1 24
$16.4M
$34.8M
Stockholders' Equity
BIOX
BIOX
VEL
VEL
Q4 25
$672.5M
Q3 25
$288.3M
$634.3M
Q2 25
$597.9M
Q1 25
$345.0M
$563.2M
Q4 24
$346.3M
$516.9M
Q3 24
$346.0M
$484.6M
Q2 24
$471.3M
Q1 24
$348.5M
$452.9M
Total Assets
BIOX
BIOX
VEL
VEL
Q4 25
$7.4B
Q3 25
$734.9M
$7.0B
Q2 25
$6.5B
Q1 25
$798.2M
$6.0B
Q4 24
$835.2M
$5.5B
Q3 24
$827.3M
$5.2B
Q2 24
$4.9B
Q1 24
$836.1M
$4.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
VEL
VEL
Operating Cash FlowLast quarter
$14.4M
$18.2M
Free Cash FlowOCF − Capex
$17.9M
FCF MarginFCF / Revenue
34.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
0.52×
TTM Free Cash FlowTrailing 4 quarters
$40.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
VEL
VEL
Q4 25
$18.2M
Q3 25
$14.4M
$11.5M
Q2 25
$7.7M
Q1 25
$23.3M
$3.5M
Q4 24
$-5.4M
$37.8M
Q3 24
$5.2M
$-17.6M
Q2 24
$11.5M
Q1 24
$-17.4M
$10.6M
Free Cash Flow
BIOX
BIOX
VEL
VEL
Q4 25
$17.9M
Q3 25
$11.4M
Q2 25
$7.6M
Q1 25
$3.5M
Q4 24
$37.5M
Q3 24
$-17.6M
Q2 24
$11.4M
Q1 24
$10.5M
FCF Margin
BIOX
BIOX
VEL
VEL
Q4 25
34.6%
Q3 25
23.2%
Q2 25
15.9%
Q1 25
9.2%
Q4 24
96.4%
Q3 24
-50.3%
Q2 24
35.1%
Q1 24
35.8%
Capex Intensity
BIOX
BIOX
VEL
VEL
Q4 25
0.5%
Q3 25
0.1%
Q2 25
0.2%
Q1 25
0.2%
Q4 24
0.7%
Q3 24
0.2%
Q2 24
0.3%
Q1 24
0.1%
Cash Conversion
BIOX
BIOX
VEL
VEL
Q4 25
0.52×
Q3 25
0.45×
Q2 25
0.29×
Q1 25
0.19×
Q4 24
-8.85×
1.81×
Q3 24
-1.11×
Q2 24
0.78×
Q1 24
-1.78×
0.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIOX
BIOX

Segment breakdown not available.

VEL
VEL

Related Party$19.3M37%
Nonrelated Party$16.9M33%
Other$15.4M30%

Related Comparisons